Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.JTO Clinical and Research Reports|June 20, 2022
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief ReportYuanbin Chen, Luis Paz-Ares, Niels Reinmuth, et al.Advances in Therapy|October 17, 2018
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid TumoursRuth Plummer, Henk M Verheul, Filip Y F L De Vos, et al.British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.Journal of Cardiovascular Pharmacology|July 22, 2025
Perspectives on artificial intelligence in medical publishing: a survey of medical journal editorsGiuseppe Biondi-Zoccai, Attilio Lauretti, Stefan Agewall, et al.Clinical Obesity|December 14, 2024
An international Delphi consensus on patient preparation for metabolic and bariatric surgeryDanielle R Clyde, Reza Adib, Sarfaraz Baig, et al.Pageof 5